Evaluation of SPN 812 ER 100 and 200 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 18 Dec 2018 Status changed from recruiting to completed.
- 06 Dec 2018 Primary endpoint (Efficacy of SPN-812 ER assessed by ADHD -RS-5 Rating Scale) has been met, according to a Supernus Pharmaceuticals media release.
- 06 Dec 2018 Results presented in the Supernus Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History